Arbutus Biopharma Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 14.24 million compared to USD 2.33 million a year ago. Net loss was USD 14.19 million compared to USD 19.39 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.23 a year ago.
For the six months, revenue was USD 26.82 million compared to USD 4.44 million a year ago. Net loss was USD 29.96 million compared to USD 35.77 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.44 a year ago.